NVS
Novartis AG
$153.58
-0.06
(-0.04%)
Mkt Cap
292.62B
Volume
576,390
52W Range
121.57-170.46
Sector
Healthcare
Beta
0.42
EPS (TTM)
6.66 USD
P/E Ratio
23.12
Revenue (TTM)
55.63B USD
Rev Growth (5Y)
+1.9%
EPS Growth (5Y)
+15.4%
AlphaVal · Fair Value
What we estimate one share is worth
$100.66
Overvalued
strong signal
52.9% above fair value
Modeled from cash flows & growth.
AlphaQuality · Grade
How strong & durable the business is
A-
Stable Earnings Power
81.1 / 100 composite
Steady, predictable earnings power — graded A–F vs. similar companies.
Company Description
Novartis AG is a holding company, which engages in the business of developing, manufacturing, and marketing healthcare products. Its product portfolio is heavily focused on innovative prescription medicines, especially oncology, immunology, neuroscience, and cardiovascular diseases, supplemented by established older brands and a wide range of specialized therapies. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.
Track Record
Showing latest 4 periods • Swipe for more
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 54.81B | 51.72B | 46.66B | 43.46B | 43.97B | 49.90B | 48.68B | 46.10B | 43.40B | 49.44B | 50.39B | 53.63B |
| Net Income | 14.06B | 11.94B | 14.85B | 6.96B | 24.02B | 8.07B | 11.73B | 12.61B | 7.70B | 6.71B | 17.78B | 10.21B |
| EPS | 7.25 | 5.92 | 7.15 | 3.19 | 10.71 | 3.54 | 3.12 | 5.44 | 3.28 | 2.82 | 7.40 | 4.21 |
| Free Cash Flow | 17.69B | 13.80B | 11.71B | 12.00B | 12.52B | 11.06B | 11.37B | 10.92B | 9.88B | 8.60B | 8.05B | 10.19B |
| FCF / Share | 9.12 | 6.84 | 5.64 | 5.50 | 5.58 | 4.86 | 4.96 | 4.71 | 4.21 | 3.61 | 3.35 | 4.20 |
| Operating CF | 19.24B | 17.62B | 14.46B | 14.24B | 15.07B | 13.65B | 13.62B | 14.27B | 12.62B | 11.47B | 11.90B | 13.90B |
| Total Assets | 115.57B | 102.25B | 99.94B | 117.45B | 131.79B | 132.19B | 118.41B | 145.56B | 133.08B | 130.12B | 131.56B | 125.39B |
| Total Debt | 37.03B | 31.26B | 26.35B | 27.91B | 31.02B | 37.85B | 29.15B | 32.09B | 28.43B | 23.80B | 21.93B | 20.41B |
| Cash & Equiv | 11.44B | 11.46B | 13.39B | 7.52B | 12.41B | 9.66B | 11.11B | 13.27B | 8.86B | 7.01B | 4.67B | 13.02B |
| Book Value | 46.13B | 44.05B | 46.67B | 59.34B | 67.66B | 56.60B | 55.47B | 78.61B | 74.17B | 74.83B | 77.05B | 70.77B |
| Return on Equity | 0.30 | 0.27 | 0.32 | 0.12 | 0.36 | 0.14 | 0.21 | 0.16 | 0.10 | 0.09 | 0.23 | 0.14 |
| Metric | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 14.42B | 13.52B | 13.33B | 14.36B | 14.84B | 13.62B | 13.56B | 13.17B | 12.87B | 12.12B | 11.78B | 12.09B |
| Net Income | 3.27B | 3.16B | 2.41B | 3.93B | 4.04B | 3.61B | 2.82B | 3.19B | 3.25B | 2.69B | 8.48B | 1.76B |
| EPS | 1.71 | 1.65 | 1.26 | 2.04 | 2.07 | 1.83 | 1.42 | 1.58 | 1.60 | 1.32 | 4.14 | 0.85 |
| Free Cash Flow | 5.57B | 2.87B | 1.64B | 5.74B | 6.11B | 2.15B | 3.06B | 5.49B | 4.15B | 1.11B | 2.14B | 5.26B |
| FCF / Share | 2.92 | 1.50 | 0.86 | 2.98 | 3.13 | 1.09 | 1.54 | 2.73 | 2.04 | 0.54 | 1.04 | 2.55 |
| Operating CF | 5.89B | 3.68B | 2.25B | 6.57B | 6.66B | 3.65B | 4.19B | 6.29B | 4.88B | 2.27B | 2.55B | 5.38B |
| Total Assets | 122.03B | 118.53B | 115.57B | 107.29B | 104.39B | 99.94B | 102.25B | 103.52B | 97.50B | 94.33B | 103.82B | 112.70B |
| Total Debt | 49.01B | 47.00B | 37.11B | 32.02B | 32.64B | 31.27B | 31.26B | 32.16B | 28.99B | 27.28B | 26.35B | 25.19B |
| Cash & Equiv | 7.62B | 6.88B | 11.44B | 9.56B | 6.66B | 7.07B | 11.46B | 13.61B | 7.90B | 9.47B | 13.39B | 12.40B |
| Book Value | 41.54B | 38.51B | 46.13B | 44.33B | 41.98B | 38.37B | 44.05B | 43.32B | 41.73B | 39.67B | 46.67B | 38.16B |
| Return on Equity | 0.08 | 0.08 | 0.05 | 0.09 | 0.10 | 0.09 | 0.06 | 0.07 | 0.08 | 0.07 | 0.18 | 0.05 |
NVS News
NVS Wins FDA Nod for Label Expansion of Immunology Drug Rhapsido
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Novartis AG - NVS
US FDA expands use of Novartis drug for chronic skin condition
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Novartis AG - NVS
Novartis Strengthens RNA Therapeutics Pipeline With $7.8B Abogen Deal
Big Pharma turns to China for new drugs as patent cliff drives multibillion-dollar deals
Novartis to License Drug From China's Abogen in Up to $7.8 Billion Deal
Novartis signs mRNA deal for about $7.8 billion with China's Abogen
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Novartis AG - NVS
Novartis AG (NVS) Shares Fall 0.8% -- What GF Score of 78 Tells Investors